青岛海尔生物医疗股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 证券代码：688139 证券简称：海尔生物 公告编号：2025-043 （一） 审议通过《关于审议公司 2025 年半年度报告及摘要的议案》 经审议，公司监事会认为：公司 2025 年半年度报告及摘要的编制和审议程 序符合法律法规、《青岛海尔生物医疗股份有限公司章程》和公司内部管理制度 的各项规定。公司 2025 年半年度报告及摘要能够客观、真实地反映公司 2025 年半年度的经营情况，公司 2025 年半年度报告及摘要所披露的信息真实、准确、 完整，不存在任何虚假记载、误导性陈述或重大遗漏。 公司 2025 年半年度报告及摘要的内容详见与本公告同日在上海证券交易所 网站（http://www.sse.com.cn）披露的《青岛海尔生物医疗股份有限公司 2025 年半年度报告》和《青岛海尔生物医疗股份有限公司 2025 年半年度报告摘要》。 表决结果：同意 3 票，反对 0 票，弃权 0 ...

Core Viewpoint - The report outlines the progress and achievements of Qingdao Haier Biomedical Co., Ltd. in its "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" initiative for the first half of 2025, emphasizing the company's focus on AI integration, innovation, and market expansion to enhance competitiveness and shareholder value [1]. Group 1: Development and Innovation - The company accelerated the development of new productive forces, focusing on four major industries and enhancing global market competitiveness through an upgraded "four horizontal and four vertical" open R&D innovation system [1][2]. - The AI foundation is being strengthened with a multi-layered architecture that integrates AI technology with life sciences and medical innovation, resulting in the creation of 17 specialized intelligent agents across various fields [2][3]. - R&D investment reached 160 million yuan, accounting for 13.39% of revenue, with a 6% reduction in new product development cycles and a 48% increase in the number of invention patents [3]. Group 2: Product Solutions and Market Performance - In the low-temperature storage industry, the company launched innovative solutions focusing on automation and intelligence, achieving recognition from users and implementing various automated sample storage solutions across multiple institutions [4]. - The laboratory solutions sector saw breakthroughs with AI-driven automation, significantly improving the efficiency of PBMC separation and cell culture processes [4]. - The smart medication sector introduced several automated solutions, expanding services to over 300 medical institutions and achieving breakthroughs in overseas markets [5]. - The blood technology sector developed a new disposable leukocyte-reducing blood bag and an automated blood component separation machine, enhancing operational efficiency and safety for healthcare professionals [6]. Group 3: Market Expansion - Despite a 14.64% decline in domestic revenue to 761 million yuan, the company improved its market share in low-temperature storage and established a leading position in several new product categories [6][7]. - The overseas market showed strong growth, with revenue reaching 427 million yuan, a 30.17% increase year-on-year, and a 56.67% increase in the second quarter [7][8]. - The company implemented localized strategies in overseas markets, achieving significant product certifications and establishing local operational platforms in multiple countries [8]. Group 4: Corporate Governance and Investor Relations - The company enhanced its governance structure and compliance with legal regulations, holding multiple board meetings to ensure operational transparency and fairness [9][10]. - Investor relations activities included over 60 interactions with institutional investors, enhancing communication and transparency regarding the company's long-term value [10][11]. - The company has maintained a consistent dividend policy, with a total dividend payout of 788 million yuan since its listing, and initiated a new share repurchase plan to boost investor confidence [11][12]. Group 5: Employee Engagement and Incentives - The company adopted a "user value creation" model to maximize employee value, linking core staff incentives to company performance through a stock incentive plan [14].

Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]

Core Viewpoint - Haier Biomedical is experiencing significant growth driven by its diversified business model and technological advancements in the life sciences and medical device sectors, with a focus on low-temperature storage, smart medication, and laboratory solutions [2][8]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical reported a revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [2]. - The revenue from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in the first half of 2025, marking a year-on-year increase of 7.27 percentage points [3]. Group 2: Industry Position and Innovations - Haier Biomedical holds a leading position in various segments, with its smart medication market share ranking among the top three in the industry, and over 50% market share in blood plasma collection solutions [4]. - The company has introduced innovative products such as a disposable leukocyte-reducing blood bag and an automated blood component separator, enhancing customer loyalty and profitability [4]. Group 3: Technological Advancements - The company has increased its R&D investment by 11.61%, accounting for 13.39% of its revenue, focusing on AI technology integration and new product development [6]. - Haier Biomedical has established a multi-layer AI infrastructure, enabling deep integration of AI with various applications, such as the IncGPT-Med model for smart medication [6][7]. Group 4: Growth Strategy - The growth strategy is based on optimizing industry structure, expanding overseas, and leveraging both internal development and external acquisitions [8][9]. - The company has expanded its presence to over 150 countries, with a notable 30% year-on-year increase in overseas revenue during the reporting period [8]. Group 5: Future Outlook - Haier Biomedical aims to enhance its global competitiveness by focusing on four major industries and accelerating the development of innovative products and solutions [9].

Core Viewpoint - Haier Biomedical is experiencing significant growth through its diversified industrial structure and digital transformation strategy, achieving a revenue of 1.196 billion yuan and a net profit of 143 million yuan in the first half of 2025, driven by the synergy of four major industries and AI technology [1] Group 1: Industrial Performance - The company has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with new industries (smart medication, blood technology, laboratory solutions) accounting for 47% of revenue in the first half of 2025, up from 38% in 2023 [2] - Each industry has established a leading position in its respective segment, with the smart medication sector addressing hospital drug management inefficiencies and achieving a top-three market share in automated medication [3] - The blood technology sector holds over 50% market share in plasma collection, introducing new products that enhance customer loyalty and profitability [3][4] Group 2: Technological Advancements - The company is leveraging AI and digital technologies to create a competitive edge, with R&D investment increasing by 11.61% to 13.39% of revenue, focusing on AI integration and new product development [5] - A multi-layered AI architecture has been established, enabling deep integration of AI with various applications, such as the IncGPT-Med model that improves medication handling efficiency [5][6] - The company has seen a 48% increase in patent applications and has established two new R&D centers, reinforcing its technological barriers [6] Group 3: Growth Strategy - The growth potential of Haier Biomedical is driven by a combination of industrial structure optimization, overseas expansion, and internal and external growth strategies [7] - The company has expanded its presence to over 150 countries, with a 30% year-on-year increase in overseas revenue, particularly benefiting from localized strategies in emerging markets [7][8] - Continuous R&D investment and strategic acquisitions have strengthened the company's capabilities in low-temperature storage and laboratory solutions, while also rapidly building platforms in smart medication and blood technology [8]

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, covering low-temperature storage, smart medication, blood technology, and laboratory solutions [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1] Business Transformation - The revenue share from new industries (smart medication, blood technology, laboratory solutions, etc.) increased from 38% in 2023 to 47% in the first half of 2025, a year-on-year increase of 7.27 percentage points [1] International Expansion - The company's products are now available in over 150 countries and regions, with five new localized platforms established in Japan, Brazil, and others during the reporting period [1] - The localized strategy has shown significant results, with overseas revenue growing by over 30% year-on-year, and the second quarter's revenue scale and growth rate reaching a new high for 2023 [1]

格隆汇8月26日丨海尔生物(688139.SH)发布2025年半年度报告，报告期实现营业收入11.96亿元，同比下 降2.27%；归属上市公司股东的净利润1.43亿元，同比下降39.09%；扣除非经常性损益后的归属于上市 公司股东的净利润1.23亿元，同比下降41.68%；基本每股收益0.45元。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-043 青岛海尔生物医疗股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第三届监事会第六次会议于 2025 年 8 月 26 日下午 14:00 以现场结合通 讯方式召开，现场会议在青岛市崂山区盈康一生大厦 19 楼会议室举行。本次会 议的通知于 2025 年 8 月 15 日以电子邮件方式送达全体监事。本次会议应出席监 事 3 人，实际出席监事 3 人，会议由江兰主持。会议的召集和召开程序符合有关 法律法规、规范性文件和公司章程的规定，会议决议合法、有效。 二、监事会会议审议情况 本次会议由江兰主持，经全体监事认真审议并表决，本次会议通过了如下议 案： （一） 审议通过《关于审议公司 2025 年半年度报告及摘要的议案》 公司 2025 年半年度报告及摘要的内容详见与本公告同日在上海证券交易所 网站（http:/ ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 1.195 billion, a decrease of 2.27% compared to the same period last year[17]. - Total profit decreased by 39.66% year-on-year to CNY 156.19 million, while net profit attributable to shareholders fell by 39.09% to CNY 142.74 million[17]. - The net cash flow from operating activities decreased by 39.87% to CNY 35.64 million, primarily due to increased operating expenses[19]. - Basic earnings per share fell by 39.19% to CNY 0.45[18]. - The company's net profit after deducting the impact of share-based payments for the first half of the year is CNY 149,638,753.59, a decrease of 38.11% compared to the same period last year[25]. - The company reported a total profit of CNY 156,193,043.70 for the first half of 2025, down from CNY 258,868,887.07 in the same period of 2024[173]. - The net profit for the first half of 2025 was CNY 147,213,041.40, down 38.4% from CNY 239,137,127.93 in the first half of 2024[173]. - The total operating profit for the first half of 2025 was CNY 5,840,349.77, compared to CNY 129,483,050.75 in the same period of 2024, indicating a significant decline[177]. Revenue and Market Performance - The company's overseas market revenue reached CNY 427 million, representing a year-on-year increase of 30.17%, with the second quarter achieving the highest revenue and growth rate since 2023[19]. - In the first half of 2025, the company achieved a main business revenue of 1.188 billion yuan, with the life sciences segment contributing 599 million yuan and the medical innovation segment contributing 589 million yuan[57]. - Domestic revenue was 761 million yuan, showing a low double-digit year-on-year decline, but the company expects a long-term positive trend driven by industry recovery and increased localization rates[58]. - New industries accounted for 47% of total revenue, achieving a year-on-year growth of 7.27%, with the company holding over 50% market share in plasma collection solutions[59]. - The company's gross profit margin was 46.28%, influenced by new factory ramp-up and an increase in material gross profit margin by 1.4 percentage points[61]. Research and Development - The R&D investment as a percentage of operating revenue increased to 13.39%, up by 1.66 percentage points from the previous year[18]. - The company has accumulated 1,596 patents, focusing on core technologies such as multi-parameter high-precision control and high-speed centrifugation[28]. - The company has established a "four horizontal and four vertical" open innovation system to enhance R&D efficiency and accelerate product innovation[62]. - R&D expenses accounted for 13.39% of revenue, with a year-on-year increase in the number of invention patents by 48%[64]. - The company has invested over 10% of its revenue in R&D annually, employing 828 R&D personnel as of the end of the reporting period[83]. - The company reported a total R&D investment of ¥160,107,590.16, representing an increase of 11.61% compared to the previous year[99]. Assets and Liabilities - Total assets decreased by 3.03% to CNY 5.612 billion compared to the end of the previous year[17]. - The net assets attributable to shareholders decreased by 1.45% to CNY 4.308 billion compared to the end of the previous year[17]. - The company's total liabilities reached CNY 1,087,643,059.53, an increase from CNY 962,455,306.44 in the previous year[170]. - Total liabilities decreased from ¥1,169,332,762.22 to ¥1,053,709,079.97, reflecting a decline of about 10%[167]. - The total amount of raised funds as of the end of the reporting period is CNY 1,231,031,108, with a net amount of CNY 1,156,905,698 after deductions[140]. Market Expansion and Global Presence - The company has established localized operations in 17 countries, including the UK, the US, and Japan, to better serve regional user needs[29]. - The company has a global business presence, with products and solutions applied in over 150 countries and regions, including partnerships with WHO and UNICEF[29]. - The company is actively expanding its global market presence to reduce operational risks associated with industry policy changes[111]. - The company has established experience training centers in regions such as the UAE, Nigeria, Singapore, and the UK, enhancing user engagement[87]. Innovations and Technology - The company has developed digital scene solutions such as smart blood use and smart vaccination, integrating IoT, cloud computing, and AI technologies[28]. - The AI-driven model "IncGPT-Biobank" was developed to improve efficiency in biobank management, achieving an 80% increase in inventory efficiency and a 50% increase in access efficiency[65]. - The company has developed a comprehensive digital solution for blood use and vaccine administration, integrating IoT, cloud computing, and AI technologies[85]. - The company has developed an innovative automated vaccine sorting and storage system, enhancing reliability in vaccine management and addressing cold chain issues[92]. Financial Risks and Management - The company faces potential financial risks from foreign exchange fluctuations, particularly in its export business, which is primarily settled in foreign currencies[110]. - The company aims to enhance its supply chain by optimizing transportation methods and expanding its supplier network to mitigate raw material supply risks[108]. - The company has made commitments to fill the dilution of immediate returns as outlined in the prospectus[133]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 12,814[153]. - The largest shareholder, Qingdao Haier Biomedical Co., Ltd., holds 100,591,463 shares, representing 31.64% of the total shares[157]. - The company did not experience any changes in the total number of ordinary shares or share capital structure during the reporting period[152].

证券代码：688139 证券简称：海尔生物 公告编号：2025-044 青岛海尔生物医疗股份有限公司 | | | 1 | 2019年10月22日实际到账的募集资金 | 1,161,576,074.14 | | --- | --- | | 减：支付的其他发行费用 | 4,670,375.54 | | 募集资金净额 | 1,156,905,698.60 | | 减：募投项目支出金额 | 1,029,056,832.19 | | 其中：以前年度累计使用的募集资金 | 988,378,129.28 | | 本年度投入募投项目支出 | 40,678,702.91 | | 减：永久补充流动资金 | 124,550,000.00 | | 减：期末用于现金管理的暂时闲置募集资金金额 | 87,840,000.00 | | 加：募集资金现金管理产品累计收益金额 | 72,784,401.15 | | 加：累计利息收入扣除手续费金额 | 11,808,991.14 | | 截至2025年6月30日募集资金余额 | 52,258.70 | 2025 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在 ...